From Bortezomib to Other Inhibitors of the Proteasome and Beyond

Current Pharmaceutical Design - United Arab Emirates
doi 10.2174/1381612811319220012
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Bentham Science Publishers Ltd.

Related search

Resistance to Proteasome Inhibitors and Other Targeted Therapies in Myeloma

British Journal of Haematology
Hematology
2018English

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib

PLoS ONE
Multidisciplinary
2013English

Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2005English

Novel Strategies in the Treatment of Multiple Myeloma: From Proteasome Inhibitors to Immunotherapy

Journal of Cell Science & Therapy
2010English

Nelfinavir Augments Proteasome Inhibition by Bortezomib in Myeloma Cells and Overcomes Bortezomib and Carfilzomib Resistance

Blood Cancer Journal
OncologyHematology
2013English

Inhibition of Proteasome Deubiquitinase Activity: A Strategy to Overcome Resistance to Conventional Proteasome Inhibitors?

Drug Resistance Updates
Cancer ResearchOncologyInfectious DiseasesPharmacology
2015English

Synthesis and Activity of Proteasome Inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry
MedicineDrug DiscoveryPharmacology
2013English

Sensitizing Human Multiple Myeloma Cells to the Proteasome Inhibitor Bortezomib by Novel Curcumin Analogs

International Journal of Molecular Medicine
MedicineGenetics
2011English

Caspase Activation and Apoptosis in Response to Proteasome Inhibitors

Cell Death and Differentiation
Cell BiologyMolecular Biology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy